Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: A meta-analysis of randomized controlled trials for 1 to 2 years

Journal of Diabetes and its Complications

Volumn 29, Issue 8, 2015, Pages 1295-1303

  Liu, Xiang Yang ^a   Zhang, Ning ^b   Chen, Rui ^a   Zhao, Jia Guo ^c   Yu, Pei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Chinese PLA 254 Hospital   (China)

^c TIANJIN HOSPITAL   (China)

Author keywords

Efficacy; Meta analysis; Safety; Sodium Glucose cotransporter 2 inhibitors; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; ORAL ANTIDIABETIC AGENT; PLACEBO; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BODY WEIGHT; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY DISEASE; LONG TERM CARE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; HYPERGLYCEMIA; HYPERTENSION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVERWEIGHT; PATIENT DROPOUT; TIME FACTOR;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; MIDDLE AGED; OVERWEIGHT; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS;

EID: 84948716657     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.07.011     Document Type: Article

References (47)

1. C.J. Bailey, J.L. Gross, D. Hennicken, N. Iqbal, T.A. Mansfield, and J.F. List Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial BMC Medicine 11 2013 43
2. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
3. W.L. Baker, L.R. Smyth, D.M. Riche, E.M. Bourret, K.W. Chamberlin, and W.B. White Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis Journal of the American Society of Hypertension 8 2014 262 275.e9
4. A.H. Barnett Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus Postgraduate Medicine 125 2013 92 100
5. A.H. Barnett, A. Mithal, J. Manassie, R. Jones, H. Rattunde, H.J. Woerle, and et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial The Lancet Diabetes & Endocrinology 2 2014 369 384
6. J.N. Basile The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM) Journal of Diabetes and its Complications 27 2013 280 286
7. M. Biljana, M. Jelena, J. Branislav, and R. Milorad Bias in meta-analysis and funnel plot asymmetry Studies in Health Technology and Informatics 68 1999 323 328
8. B. Bode, K. Stenlof, S. Harris, D. Sullivan, A. Fung, K. Usiskin, and et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes Diabetes, Obesity & Metabolism 17 2015 294 303
9. J. Bolinder, O. Ljunggren, L. Johansson, J. Wilding, A.M. Langkilde, C.D. Sjostrom, and et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes, Obesity & Metabolism 16 2014 159 169
10. R.K. Campbell Fate of the beta-cell in the pathophysiology of type 2 diabetes Journal of the American Pharmacists Association: JAPhA 49 Suppl. 1 2009 S10 S15
11. W.T. Cefalu, L.A. Leiter, K.H. Yoon, P. Arias, L. Niskanen, J. Xie, and et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 Week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950
12. E.C. Chao, and R.R. Henry SGLT2 inhibition - A novel strategy for diabetes treatment Nature Reviews. Drug Discovery 9 2010 551 559
13. R.A. Defronzo Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
14. D. Devineni, L. Morrow, M. Hompesch, D. Skee, A. Vandebosch, J. Murphy, and et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes, Obesity & Metabolism 14 2012 539 545
15. E. Dietrich, J. Powell, and J.R. Taylor Canagliflozin: A novel treatment option for type 2 diabetes Drug Design, Development and Therapy 7 2013 1399 1408
16. M. Egger, S.G. Davey, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
17. E. Ferrannini, A. Berk, S. Hantel, S. Pinnetti, T. Hach, H.J. Woerle, and et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes Diabetes Care 36 2013 4015 4021
18. E. Ferrannini, S.J. Ramos, A. Salsali, W. Tang, and J.F. List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
19. T.C. Hardman, and S.W. Dubrey Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes Diabetes Therapy 2 2011 133 145
20. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Statistics in Medicine 21 2002 1539 1558
21. N. Inagaki, K. Kondo, T. Yoshinari, N. Maruyama, Y. Susuta, and H. Kuki Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study Diabetes, Obesity & Metabolism 15 2013 1136 1145
22. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, and et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 2015 140 149
23. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 17 1996 1 12
24. C.H. Jung, J.E. Jang, and J.Y. Park A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor Diabetes & Metabolism Journal 38 2014 261 273
25. B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, L. Li, and et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clinical Pharmacology and Therapeutics 85 2009 520 526
26. B. Komoroski, N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clinical Pharmacology and Therapeutics 85 2009 513 519
27. E. Kurosaki, and H. Ogasawara Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data Pharmacology & Therapeutics 139 2013 51 59
28. F.J. Lavalle-Gonzalez, A. Januszewicz, J. Davidson, C. Tong, R. Qiu, W. Canovatchel, and et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial Diabetologia 56 2013 2582 2592
29. L.A. Leiter, W.T. Cefalu, T.W. de Bruin, I. Gause-Nilsson, J. Sugg, and S.J. Parikh Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension Journal of the American Geriatrics Society 62 2014 1252 1262
30. A. Liakos, T. Karagiannis, E. Athanasiadou, M. Sarigianni, M. Mainou, K. Papatheodorou, and et al. Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis Diabetes, Obesity & Metabolism 16 2014 984 993
31. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
32. A. Lundh, S. Sismondo, J. Lexchin, O.A. Busuioc, and L. Bero Industry sponsorship and research outcome Cochrane Database of Systematic Reviews 12 2012 MR000033
33. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease Journal of the National Cancer Institute 22 1959 719 748
34. D. Moher, S. Hopewell, K.F. Schulz, V. Montori, P.C. Gotzsche, P.J. Devereaux, and et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials Journal of Clinical Epidemiology 63 2010 e1 e37
35. G. Musso, R. Gambino, M. Cassader, and G. Pagano A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials Annals of Medicine 44 2012 375 393
36. M.A. Nauck, P.S. Del, S. Duran-Garcia, K. Rohwedder, A.M. Langkilde, J. Sugg, and et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin Diabetes, Obesity & Metabolism 16 2014 1111 1120
37. M.A. Nauck, P.S. Del, J.J. Meier, S. Duran-Garcia, K. Rohwedder, M. Elze, and et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 2011 2015 2022
38. L.E. Nicolle, G. Capuano, A. Fung, and K. Usiskin Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor Postgraduate Medical Journal 126 2014 7 17
39. M. Ridderstrale, K.R. Andersen, C. Zeller, G. Kim, H.J. Woerle, and U.C. Broedl Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial The Lancet Diabetes & Endocrinology 2 2014 691 700
40. J. Rosenstock, A. Jelaska, G. Frappin, A. Salsali, G. Kim, H.J. Woerle, and et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 37 2014 1815 1823
41. A.J. Scheen Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus Drugs 75 2015 33 59
42. G. Schernthaner, J.L. Gross, J. Rosenstock, M. Guarisco, M. Fu, J. Yee, and et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial Diabetes Care 36 2013 2508 2515
43. Y.N. Sun, Y. Zhou, X. Chen, W.S. Che, and S.W. Leung The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomised controlled trials BMJ Open 4 2014 e004619
44. D. Vasilakou, T. Karagiannis, E. Athanasiadou, M. Mainou, A. Liakos, E. Bekiari, and et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis Annals of Internal Medicine 159 2013 262 274
45. J.P. Wilding, G. Charpentier, P. Hollander, G. Gonzalez-Galvez, C. Mathieu, F. Vercruysse, and et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial International Journal of Clinical Practice 67 2013 1267 1282
46. J.P. Wilding, V. Woo, K. Rohwedder, J. Sugg, and S. Parikh Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years Diabetes, Obesity & Metabolism 16 2014 124 136
47. Q. Zhang, J. Dou, and J. Lu Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses Diabetes Research and Clinical Practice 105 2014 313 321